-
Featured Press Release
Aspira Women’s Health Reports First Quarter 2021 Financial Results
Learn More -
Press Release
Aspira Women’s Health to Reveal 3rd Generation Ovarian Cancer Risk Assessment Technology at ASCO 2021
Learn More -
Press Release
Aspira Women’s Health Initiates Prospective Clinical Study for Benign Risk Monitoring and High Risk Early Ovarian Cancer Detection with Northwell Health®
Learn More
Press Release
Choose a Category:
-
Aspira Women’s Health Releases Analytical and Initial Clinical Validation Performance for OVASight at ASCO 2021
Press Release
For a PDF version of this press release, click here. Data demonstrates the performance of OVASight in a low prevalence population-89% Specificity, 91% Sensitivity and a Negative Predictive Value of 99.6%for the management of suspected Benign Pelvic Masses AUSTIN, Texas; June 3, 2021 – Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company focused on…
-
Aspira Women’s Health Inc. to Participate in the William Blair Growth Stock Conference
Press Release
For a PDF of this press release, click here. AUSTIN, Texas — May 19, 2021 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that management will participate in and present at the William Blair Growth Stock Conference on June 1-3, 2021. Details for the event are below: William Blair…
-
Aspira Women’s Health Reports First Quarter 2021 Financial Results
Press Release
Conference call scheduled for today, May13 at 4:30 p.m. ET For a PDF of this press release, click here. AUSTIN, Texas — May 13, 2021 — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the first quarter ended, March 31, 2021. “We…
-
Aspira Women’s Health to Reveal 3rd Generation Ovarian Cancer Risk Assessment Technology at ASCO 2021
Press Release
For a PDF of this press release, click here. Analytical and Initial Clinical Validation performance for Aspira’s OVASightTM blood-based biomarker test for Ovarian Malignancy risk assessment in women with Adnexal Masses. Data demonstrates the ability to identify Ovarian Cancer Risk in a low prevalence population. AUSTIN, Texas; May 13, 2021 – Aspira Women’s Health, Inc. (Nasdaq:…
-
Aspira Women’s Health Initiates Prospective Clinical Study for Benign Risk Monitoring and High Risk Early Ovarian Cancer Detection with Northwell Health®
Press Release
For a PDF version of this press release, click here. Study Evaluates a 3rd Generation Multivariate Index Assay for serial monitoring women with a benign pelvic mass as well as the expansion of our development of our proteogenomic test for early-stage detection of ovarian cancer in high risk Ovarian Cancer patients. AUSTIN, Texas; May 12, 2021 –…